×
The companies using AI to discover and design new drugs
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

Artificial Intelligence and biotechnology are converging to create breakthrough developments in drug discovery and clinical treatments, with multiple companies reporting significant progress in AI-designed therapeutics.

Major breakthrough in AI drug development: Insilico Medicine has announced promising results from a clinical trial of its AI-designed drug ISM001-055, targeting idiopathic pulmonary fibrosis, a devastating lung condition affecting approximately 100,000 Americans.

  • The phase IIa study included 71 patients across different dosage groups, with the highest dose group showing improved lung function compared to placebo
  • Most reported side effects were mild to moderate across all patient groups
  • Patients receiving the 60mg dose demonstrated enhanced quality of life metrics

Enveda’s nature-inspired AI approach: Colorado-based Enveda has launched its first clinical trial for ENV-294, representing a novel fusion of traditional medicine and advanced AI technology.

  • The company uses AI models trained on biological data to identify therapeutic compounds found in nature
  • Their innovative approach employs mass spectrometry and transformer models to rapidly analyze natural compounds
  • ENV-294, derived from plant-based anti-inflammatory molecules, offers a potentially safer alternative to existing treatments

Industry partnerships and investments: Several major developments highlight growing confidence in AI-powered drug discovery platforms.

  • Genesis Therapeutics secured investment from Nvidia’s venture capital arm
  • Novartis initiated a collaboration with Schrödinger worth potentially $2.3 billion
  • GSK partnered with Vesalius Therapeutics in an $80 million upfront deal for Parkinson’s disease treatment development

Breakthrough research in GLP-1 medications: A comprehensive study from Finnish and Swedish researchers reveals unexpected benefits of common diabetes and obesity medications.

  • Analysis of 220,000 patients with alcohol use disorder showed reduced alcohol-related hospitalizations among those taking semaglutide or liraglutide
  • The 17-year study provides compelling data, though researchers emphasize the need for dedicated clinical trials
  • These findings suggest potential new applications for existing GLP-1 medications

Looking ahead: AI’s expanding role in healthcare: While early results from AI-designed drugs show promise, the industry is still in its early stages of leveraging artificial intelligence for drug discovery and development, with many questions remaining about long-term efficacy and scalability of these approaches.

InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug

Recent News

This AI startup aims to automate nearly all of your accounting tasks

The new AI platform addresses a critical labor shortage in accounting by automating routine tasks while keeping humans in control of financial processes.

How to use AI to set a company budget

AI-powered budgeting tools are streamlining financial forecasting, but human oversight remains crucial for strategic decisions.

AI boom could fuel 3 million tons of e-waste by 2030, research finds

New research reveals AI systems could produce up to 5 million metric tons of electronic waste by 2030, raising concerns about the environmental impact of rapidly expanding AI adoption.